fda compounded semaglutide decision & Tirzepatide 2025: Safe Use Guide FDA Warns on Certain Forms

SGLT2 inhibitors appear more effective in mitigating glomerular hyperfiltration and lowering heart failure risk, whereas GLP-1 receptor agonists are particularly beneficial in reducing albuminuria and atherosclerotic cardiovascular events

Di S, Malcher-Lopes R, Marcheselli VL, Bazan NG, Tasker JG

Despite prior evidence linking endogenous GLP-1 in the LS with increased satiety (30), the contribution of these GLP-1Rs to the pharmacological effects of liraglutide was unknown

However, this combination requires careful medical oversight to optimize dosing and minimize the risk of side effects, especially hypoglycemia (low blood sugar), which can be more likely when these medications are used together